UniQure's Huntington's gene therapy is delayed, as FDA suggests it may walk back accelerated approval blessing

UniQure's stock was in freefall Monday morning after the company announced that it might not be able to submit its Huntington’s disease gene therapy for FDA approval on the originally planned timeline. UniQure